Citations

Showing 10 of 108104 citations.

2072. Multicenter Evaluation of the Etest vs. Agar Dilution for Susceptibility Testing of Helicobacter pylori
Otiso, Joshua, Keller, George, Heule, Hillary Van, Kohner, Peggy C., Cole, Nicolynn C., Richter, Sandra S. , Couturier, Marc Roger , Shakir, Salika M. , Schuetz, Audrey N.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S605-S605

10.1093/ofid/ofy210.1728 Get It

1536. Donor-Derived Mycobacterium tuberculosis Infection After Solid-Organ Transplantation: A Comprehensive Review
Abad, Cybéle Lara R. , Razonable, Raymund R.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S476-S477

10.1093/ofid/ofy210.1364 Get It

1108. Diagnostic Yield of the BioFire FilmArray Gastrointestinal Panel in Hospitalized Children at an Academic Children’s Center
Madigan, Theresa , Rajapakse, Nipunie , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S332-S332

10.1093/ofid/ofy210.942 Get It

Abstract Background The BioFire FilmArray Gastrointestinal Panel (BioFire Diagnostics) (GIP) is a multiplex stool PCR test that detects 22 organisms. Studies in adults suggest that the diagnostic yield of the GIP in hospitalized patients is low. The utility of the GIP among hospitalized pediatric patients and indications for diagnostic stewardship of this test are not well described. Methods We conducted a retrospective chart review of hospitalized pediatric patients who had a GIP ordered between October 2015 and October 2017. Demographic, clinical, and laboratory information was extracted from the medical record. Statistical analysis was completed using JMP Pro 13.0.0 (SAS Institute Inc.). Results Over the 2-year study period, 193 GIPs were obtained on 155 individual pediatric patients. The mean patient age was 8 years and 59% were male. Forty-four percent of patients were immunocompromised and 21% had inflammatory bowel disease. The pediatric infectious disease (PID) team was consulted in 15% of patients at the time the test was ordered. The overall positivity rate of the GIP for one or more pathogens was 42% (Figure 1), with 76% of GIPs positive for one, 23% for two, and 1% for three pathogens. No parasitic infections were diagnosed. The GIP was more likely to be positive if GI symptom onset was prior to admission (48% vs. 24%, P = 0.004), if GI symptoms had been present for < 2 weeks vs. ≥2 weeks (52% vs. 20%, P = 0.0001), and if GI symptoms were the primary reason for the hospital admission (50% vs. 32%, P = 0.012). Only Clostridioides difficile or viral pathogens were detected in patients whose symptoms began in the hospital (Figure 2). Among patients with a positive test, 40% received treatment targeted at one or more of the detected pathogens (Figure 1). Enteropathogenic E.coli (EPEC) and Enteroaggregative E.coli (EAEC) were never treated (Figure 3). Conclusion The GIP was positive for one or more pathogens in 42% of hospitalized children for whom the test was ordered, and led to specific therapy in 40% of those with a positive test. EPEC and EAEC were not treated. The diagnostic yield of the GIP was higher if GI symptoms were present for <2 weeks, began before hospitalization, and were the primary reason for admission. The GIP was frequently obtained without guidance from the PID team. Disclosures R. Patel, CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company: Grant Investigator, Research grant – monies paid to Mayo Clinic. Curetis, Specific Technologies, Selux Dx, GenMark Diagnostics, PathoQuest and Genentech: Consultant and Scientific Advisor, Consulting fee – monies paid to Mayo Clinic. ASM and IDSA: Travel reimbursement and editor’s stipends, Travel reimbursement and editor’s stipends. NBME, Up-to-Date and the Infectious Diseases Board Review Course: Varies, Honoraria. Mayo Clinic: Employee, Salary.
LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+R−) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial
Singh, Nina, Winston, Drew J., Lyon, G. Marshall, Silveira, Fernanda P. , Wagener, Marilyn M., Razonable, Raymund R. , Limaye, Ajit P.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S766-S766

10.1093/ofid/ofy229.2195 Get It

Abstract Background Current guidelines preferentially recommend valganciclovir (VGCV) prophylaxis over PET in most D+R− organ transplant populations, but adequately powered direct comparative clinical trials are lacking. Methods D+R− LTR were randomly assigned (1:1, stratified by site and T-cell depleting induction) to receive either PET (weekly plasma CMV DNAemia at central laboratory for 100 days, with VGCV 900 mg bid for DNAemia at any level, until two consecutive negative weekly tests) or prophy (VGCV 900 mg qd for 100 days). The primary outcome was CMV disease by 12 months as adjudicated by an independent, blinded, endpoint committee in ITT population. Secondary outcomes were opportunistic infections (OIs) (invasive fungal and bacterial), neutropenia (ANC < 1000/µL), acute rejection, graft loss, and mortality assessed at12 months. Results From October 2012 to June 2017, 205 patients were randomized at six centers; 100 to PET, 105 to prophy. The incidence of CMV disease was 9% (9/100) in PET and 19% (20/105) in prophy (P = 0.039) with majority of difference due to post-prophylaxis disease: 6% in PET vs. 17% in prophy (P = 0.027). CMV disease included syndrome in 55% (16/29) and end-organ in 45% (13/29), with similar proportions in two groups. Secondary outcomes were not different for PET and prophy groups: OIs (19% vs. 21%), neutropenia (34% vs.. 28%), acute rejection (27% vs. 27%), graft loss (2% vs. 2%), and mortality (10% vs. 6%), respectively, P > 0.05 for all comparisons. Mortality at last follow-up (median 3.2 years) was not different for PET vs. prophy (14% vs. 18%, P = 0.43). Conclusions PET significantly reduced the incidence of CMV disease compared with prophy in D+R- LTR, and was associated with similar other clinical outcomes. Current guidelines should be revised to recommend PET over prophylaxis in this setting, and similar trials conducted in other D+R− transplant populations. (Funded by NIAID; ClinicalTrials.gov# NCT01552369.) Disclosures D. Winston, Merck: Investigator, Research support. Chimerix: Investigator, Research support. Shire: Investigator, Research support. Gilead: Investigator, Research support. Oxford Immunotech: Investigator, Research support. G. M. Lyon III, Shire: Investigator, institutional research support. Hookipa: Investigator, institutional research support. Merck: Investigator, institutional research support. F. P. Silveira, Shire: contracted clinical research, site investigator. A. P. Limaye, Merk: Consultant and Investigator, Consulting fee and Research grant. Astellas Pharma Inc.: Consultant and Investigator, Consulting fee. Helocyte Inc.: Consultant, Consulting fee.
2044. Utility of Serum Β-D Glucan Assay for Diagnosis of Invasive Fungal Infections in Solid Organ Transplant Recipients
Vijayvargiya, Prakhar , Garrigos, Zerelda Esquer , Saleh, Omar Abu , Wilhelm, Mark , Razonable, Raymund R. , Sohail, M. Rizwan

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S596-S596

10.1093/ofid/ofy210.1700 Get It

332. Phaeohyphomycosis Due to Scopulariopsis brumptii in a Hematopoietic Stem Cell Transplant (HSCT) Recipient
Syed, Sadia, Garrigos, Zerelda Esquer , Barth, Dylan M, Saleh, Omar Abu , Vijayvargiya, Prakhar , Sohail, M. Rizwan

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S132-S133

10.1093/ofid/ofy210.343 Get It

1565. Lymphocyte Subsets as Predictors of Cytomegalovirus Infection After Transplantation
Meesing, Atibordee , Razonable, Raymund R.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S488-S488

10.1093/ofid/ofy210.1393 Get It

1424. Examining the Relationship Between Vancomycin Area Under the Concentration–Time Curve and Serum Trough Levels in Adults with Presumed or Documented Staphylococcal Infections
Clark, Laura , Servais, R., Brummitt, Charles, Skrupky, Lee P. , Servais, Ryan, Dilworth, Thomas J

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S439-S440

10.1093/ofid/ofy210.1255 Get It

1587. Analysis of Breakthrough Blood Stream Infections in Left Ventricular Assist Device Recipients Managed With Chronic Antimicrobial Suppressive Therapy
Jandhyala, Deeksha , Wright, Alan J. , Walker, Randall C., Stulak, John M., Bran, Andres, Farid, Saira, O’Horo, John C. , Wright, Alan J, Baddour, Larry M. , Sohail, M Rizwan

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S497-S497

10.1093/ofid/ofy210.1415 Get It

2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
Lahr, Brian D. , Sampathkumar, Priya , Yetmar, Zachary A. , O’Horo, John C. , Behfar, Atta , Beam, Elena

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S614-S614

10.1093/ofid/ofy210.1750 Get It